Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Painkilling black mamba snake
Image: George Grall
Deadly snake venom could form strong painkiller

According to a study by french scientists, the venom of the black mamba snake could help to form a painkiller as powerful as morphine.

The black mamba snake, which derives from Africa, is one of the world's fastest and most venomous. It is a compound found in their venom, called mambalgins, which gives pain relief when isolated.

The mambalgins are expected to have no side effects in humans, making it a potential replacement for morphine, which is addictive and can cause headaches, vomiting and muscle-twitching, amongst other conditions.

The study was published in the Nature journal, following tests on mice that showed mambalgins block the central and peripheral nervous system's acid-sensing ion channels (ASICs), effectively giving pain relief.

Herpetologist and toxicologist, Zolan Takacs, said: "Animal venom toxins have a solid success rate [becoming] major drugs. There is no question this will continue, as the vast majority of toxins remain unexplored."

Study leader, Anne Baron, of the Institute of Molecular and Cellular Pharmacology in France, said: "It's remarkable that this was made possible from the deadly venom of one of the most venomous snakes."

However, Takacs added: "To develop a new drug you need 10 to 15 years hundreds of millions of dollars, and you still have no guarantees". 

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'